By Fineline Cube 
CSPC Pharmaceutical Group Limited (HKG: 1093), a China-based company, announced on September 15, 2025, that its self-developed ALMB-0166 has received approval from China’s National Medical Products Administration (NMPA) to proceed with Phase II clinical trials for the treatment of Parkinson’s disease.
ALMB-0166 Mechanism and Development
ALMB-0166, a first-in-class humanized monoclonal antibody inhibitor targeting Connexin 43 (Cx43), was developed by AlaMab Therapeutics Inc., a subsidiary of CSPC. It is designed for the treatment of neurological disorders, including Parkinson’s disease, acute ischemic stroke, and acute spinal cord injury.
Preclinical Results
Preclinical studies on sub-acute and chronic Parkinson’s animal models demonstrated that ALMB-0166 significantly inhibits the decrease of dopamine levels in the brain, restores behavioral abilities and functions, and shows a favorable dose-response relationship.-Fineline Info & Tech